Aptevo Secures $60M Equity Line, Reports Positive AML Data & FY25 Results Amidst Dilution

summarizeSummary

Aptevo Therapeutics reported full-year 2025 financial results, including a significant cash increase and past dilution, alongside positive clinical data for its AML candidate mipletamig, and established a $60 million equity line facility to extend its financial runway.

check_boxKey Events

• Secures $60 Million Equity Line

  Aptevo established a $60 million equity line facility with Yorkville Advisors Global, LP, providing significant capital access that could extend its operational runway into 2029 if fully utilized.

• Reports Positive Mipletamig AML Data

  Updated interim results for mipletamig in 28 frontline AML patients showed an 86% clinical benefit rate, including a 79% CR/CRi, with no cytokine release syndrome observed, comparing favorably to standard of care.

• Full-Year 2025 Financial Results

  The company ended 2025 with $21.6 million in cash and cash equivalents, up from $8.7 million in 2024, and reported a net loss of $26.0 million. A significant increase in shares outstanding and a non-cash dividend from warrant features indicate substantial past dilution.

• CEO Transition Announced

  Marvin White will transition to Executive Chair, with Jeff Lamothe assuming the role of President and Chief Executive Officer.

auto_awesomeAnalysis

This 8-K details Aptevo Therapeutics' full-year 2025 financial results, significant clinical progress for its lead AML candidate, and a crucial financing development. The company reported an increased cash position to $21.6 million, which, along with the establishment of a new $60 million equity line facility, provides substantial capital access and extends its operational runway into 2029 if fully utilized. However, the significant increase in shares outstanding from 2024 to 2025, and a $1.6 million non-cash dividend attributable to a 'down round' feature of warrants, highlight substantial past dilution. Concurrently, updated interim data for mipletamig in frontline AML patients showed an 86% clinical benefit rate with a favorable safety profile, including no cytokine release syndrome, which is a strong positive for its development. While the financing provides critical runway, the ongoing and potential future dilution is a key consideration for investors.